Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desmethylsibutramine is a **small molecule monoamine reuptake inhibitor** and the major active metabolite of sibutramine. It inhibits the **norepinephrine transporter** and **serotonin transporter**, increasing synaptic norepinephrine and serotonin and thereby producing anorectic effects linked to reduced appetite and altered energy balance. The compound appears to be more potent than sibutramine in neurotransmitter reuptake inhibition, but it was not developed as a standalone marketed medicine; instead, it is primarily recognized as the pharmacologically active metabolite contributing to sibutramine's anti-obesity activity and has also been reported as an undeclared adulterant in some weight-loss supplements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desmethylsibutramine.